Print Page  |  Close Window

Investor Overview

Corporate Profile

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

Latest News

May 09, 2017

Oncobiologics to Present at the World Biosimilar Congress 2017more >

April 17, 2017

Oncobiologics Secures Additional Fundingmore >

February 06, 2017

Oncobiologics Announces Term Extension of Series A Warrantsmore >

Upcoming Events

There are currently no events scheduled.